Korro Bio, Inc. (KRRO) Income Statement

The reported revenue series is sparse and volatile, with multiple quarters showing no revenue line and the only recent non-zero figures clustered in 2025. This pattern suggests revenue is episodic, likely tied to collaboration or licensing milestones rather than recurring product sales, which would make year-over-year growth rates unreliable as a signal. Investors should monitor whether any future revenue reflects durable commercial activity rather than one-time recognition events.

Because operating expenses remain largely fixed while revenue has been minimal, there is no operating leverage in the conventional sense; losses are driven by the cost base rather than scale. R&D consumes the majority of spending, which is typical for a clinical-stage biotech but means the loss trajectory depends heavily on program timing. The data does not show a path where incremental revenue meaningfully offsets current expenses.

R&D accounts for roughly two-thirds of total operating expenses in most quarters, reflecting a pipeline-driven cost structure. Stock-based compensation of $0.9M to $5.4M per quarter is a non-trivial share of SG&A and R&D, which may inflate the apparent cost base relative to cash spend. Management's expense discipline is difficult to judge from this series alone, though the decline in R&D from its 2025Q2 peak suggests some pipeline-level reprioritization may be occurring.